Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia

Cytometry Part B - Clinical Cytometry

Volumn 82 B, Issue 3, 2012, Pages 145-150

  Kern, Wolfgang ^a   Bacher, Ulrike ^b   Haferlach, Claudia ^a   Alpermann, Tamara ^a   Dicker, Frank ^a   Schnittger, Susanne ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

CD8 expression; chronic lymphocytic leukemia (CLL); fluorescence in situ hybridization (FISH); multiparameter flow cytometry; prognosis

Indexed keywords

CD8 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TRISOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; ANTIGENS, CD8; CHROMOSOME ABERRATIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84860123367     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21002     Document Type: Article

References (22)

1. Hallek M,. State-of-the-art treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2009; 1: 440-449.
2. Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S,. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438-2447.
3. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P,. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784)
4. Stilgenbauer S, Bullinger L, Lichter P, Döhner H,. Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007. (Pubitemid 34618838)
5. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S,. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416. (Pubitemid 34864299)
6. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, Lõpez-Guillermo A, Campo E, Montserrat E,. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775. (Pubitemid 36514707)
7. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis R, Henrickson S, Zhao H, Ibbotson R, Orchard J, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti G, Wilson W, Hamblin TJ, Oscier D, Staudt L,. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951. (Pubitemid 36857758)
8. Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S,. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010; 28: 4473-4479.
9. Inaba T, Shimazaki C, Sumikuma T, Okano A, Hatsuse M, Okamoto A, Ashihara E, Hibi S, Sudo Y, Yamagata N, Murakami S, Rin K, Fujita N, Yoshimura M, Nakagawa M,. Expression of T-cell-associated antigens in B-cell non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 592-599. (Pubitemid 30415187)
10. Mulligan SP, Dao LP, Francis SE, Thomas ME, Gibson J, Cole-Sinclair MF, Wolf M,. B-cell chronic lymphocytic leukaemia with CD8 expression: Report of 10 cases and immunochemical analysis of the CD8 antigen. Br J Haematol 1998; 103: 157-162. (Pubitemid 28470813)
11. Carulli G, Stacchini A, Marini A, Ciriello MM, Zucca A, Cannizzo E, Aliberti S, Demurtas A, Novero D, Calcagno L, Callegari T, Petrini M,. Aberrant expression of CD8 in B-cell non-Hodgkin lymphoma: A multicenter study of 951 bone marrow samples with lymphomatous infiltration. Am J Clin Pathol 2009; 132: 186-190.
12. Cannizzo E, Carulli G, Zucca A, Petrini M,. CD19/CD8 coexpression in B-chronic lymphocytic leukemia. Acta Haematol 2007; 117: 128.
13. Parisi-Duchêne E, Mazurier I, Moskovtchenko P,. Aberrant CD8 expression in B-chronic lymphocytic leukemia: Report of five cases. Acta Haematol 2006; 115: 74-77. (Pubitemid 43130437)
14. Stagno F, Triolo A, Del Fabro V, Berretta S, Parrinello NL, Fargione G, Raimondo F,. Aberrant phenotypic expression of the T-cell-associated antigen CD8 on B-cell chronic lymphocytic leukemia cells. Lab Hematol 2009; 15: 1-3.
15. Müller-Hermelink H, Montserrat E, Catovsky D, Campo E, Harris N, Stein H,. Chronic lymphocytic leukemia/small lymphocytic leukemia. In:, Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer (IARC) Press; 2008. pp 180-182.
16. Kern W, Dicker F, Schnittger S, Haferlach C, Haferlach T,. Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1229 patients with chronic lymphocytic leukemia. Cytometry B Clin Cytom 2009; 76B: 385-393.
17. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T,. Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442-2451. (Pubitemid 350148886)
18. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C,. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152-3160.
19. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, Davi F, Rosenquist R,. European Research Initiative on CLL. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia 2007; 21: 1-3. (Pubitemid 44921826)
20. Islam A, Vladutiu AO, Donahue T, Akhter S, Sands AM, Ambrus JL,. CD8 expression on B cells in chronic lymphocytic leukemia: A case report and review of the literature. Arch Pathol Lab Med 2000; 124: 1361-1363.
21. Kaleem Z, White G, Zutter MM,. Aberrant expression of T-cell-associated antigens on B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2001; 115: 396-403. (Pubitemid 33694837)
22. Schroers R, Pukrop T, Durig J, Haase D, Duhrsen U, Trümper L, Griesinger F,. B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. Leuk Lymphoma 2004; 45: 1677-1681. (Pubitemid 38886015)